Fig. 7: The efficacy and mechanism of TCC treatment were verified in immunocompetent mice. | Cell Death & Disease

Fig. 7: The efficacy and mechanism of TCC treatment were verified in immunocompetent mice.

From: Synergistic immunochemotherapy targeted SAMD4B-APOA2-PD-L1 axis potentiates antitumor immunity in hepatocellular carcinoma

Fig. 7

a Orthotopic tumour model and drug treatment in C57BL6/J mice. b Compared with the single drugs and the dual-drug combination, the tri-drug combination resulted in smaller tumours, regardless of tumour volume (c) and weight (d). e The flow cytometry analysis demonstrated that the lowest proportion of CD29+CD8+ T cells was associated with the tri-drug combination. f, g Combined treatment with increasing doses of drugs upregulated SAMD4B expression and downregulated the expression of APOA2, PD-L1, NOTCH1 and NOTCH2. Student’s t test (level of significance: ***P < 0.001; **P < 0.01; *P < 0.05).

Back to article page